Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 19Fallopian Tube Neoplasms 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Glioma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2pembrolizumab 1olaparib 1Tegafur 1S 1 (combination) 1Observation 1Nivolumab 1Ipilimumab 1Gemcitabine 1Cisplatin 1Capecitabine 1CTLA-4 Antigen 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bile Duct Neoplasms × olaparib × Clear all
NCT04042831 2026-05-15

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Academic and Community Cancer Research United

Phase 2 Active not recruiting
32 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡